Probiotics increasingly seen as valuable healthcare tools in SEA

0
Probiotics increasingly seen as valuable healthcare tools in SEA

As the demand for probiotics rises, so do the opportunities for healthcare companies to address gaps in knowledge and distribution.

Docquity’s community includes general practitioners, paediatricians, and neonatologists.

Its collaboration with SIT Pharma aims to boost the awareness and use of probiotics among health practitioners in Thailand, with the goal of expanding into more regions within South East Asia.

Science-backed evidence

Over the last two decades, scientific understanding of the gut microbiome has deepened. This brought new evidence that highlighted the importance of probiotics.

SIT Pharma’s duo probiotics Infloran has been available in several countries for more than 40 years. It is a pharmaceutical product containing Lactobacillus and Bifidobacterium, the two main genera of bacteria present in healthy human intestines.

“The association of these two strains [Lactobacillus acidophilus and Bifidobacterium bifidum] in a single formulation is confirmed by several clinical trials for different therapeutic indications,”​ said Lucio Beltrami, Sales and Business Development Manager at SIT Pharma.

This rising body of evidence has prompted doctors to view probiotics as more than supplements, recognising their potential in treating and preventing intestinal conditions such as viral and bacterial infections or dysbiosis.

Factors like antibiotic-associated diarrhoea and digestive issues in infants are now leading physicians to prescribe probiotics, especially in paediatrics, where gut health is crucial to overall well-being.

link

Leave a Reply

Your email address will not be published. Required fields are marked *